T1 mapping and exercise 31P-MR spectroscopy for cardiomyopathy phenotyping

T1 mapping and exercise 31P-MR spectroscopy for cardiomyopathy phenotyping - MRI for cardiomyopathy phenotyping

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39665

Enrollment

320

Registered

2012-11-02

Start date

2012-12-12

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Various types of cardiomyopathy due to genetic mutations, as well as acquired cardiomyopathies.

Exclusion criteria

Exclusion criteria: 1. Under the age of 18. 2. Have a history of claustrophobia. 3. Are anticipated not to be able be complete the exercise protocol. 4. Have renal failure (estimated glomerular filtration rate

Design outcomes

Primary

Measure	Time frame
The main study parameters are (1) T1 times as quantified by MRI, and (2) stacks of high-energy myocardial phosphate spectra as obtained by 31P-MRS at rest, during mild exercise, and during moderate exercise. For patients in category c2, response after CRT device implantation will be documented by SF36 questionnaires to quantify disease severity and quality of life, a 6 minute walking test to objectively quantify physical fitness, and by echocardiography to quantify progression or regression of left ventricular diameters and ejection fraction.	—

Measure

Time frame

The main study parameters are (1) T1 times as quantified by MRI, and (2) stacks of high-energy myocardial phosphate spectra as obtained by 31P-MRS at rest, during mild exercise, and during moderate exercise. For patients in category c2, response after CRT device implantation will be documented by SF36 questionnaires to quantify disease severity and quality of life, a 6 minute walking test to objectively quantify physical fitness, and by echocardiography to quantify progression or regression of left ventricular diameters and ejection fraction.

—

Secondary

Measure	Time frame
(1) miRNA signature	—

Countries

Netherlands

Outcome results